Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients

BACKGROUND/AIMS: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Da Hea, Cho, Yongin, Lee, Sujin, Park, Seho, Kim, Seung-Il, Park, Byeong Woo, Rhee, Yumie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506747/
https://www.ncbi.nlm.nih.gov/pubmed/28838227
http://dx.doi.org/10.3904/kjim.2016.205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506747/
https://www.ncbi.nlm.nih.gov/pubmed/28838227
http://dx.doi.org/10.3904/kjim.2016.205

Ejemplares similares